ClinicalTrials.gg
RecruitingNCT07046468SPIRITUpdated Aug 29, 2025

Smart Pill for Measuring Gut Health in Colon Inflammation and Colon Cancer

An observational study in Ulcerative Colitis (UC) and Colorectal Cancer (CRC), sponsored by Radboud University Medical Center. Recruiting at 1 site in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-29.

Sponsored by Radboud University Medical Center · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2026, 8 months ago, but the record still lists the study as recruiting.
  • Started Jul 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
10
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 164 studies in Colitis, Ulcerative with a site in Netherlands — 25 open to participants now, 44 under way, 21 of them phase 3. Colitis, Ulcerative · Netherlands.

Planned enrollment
24th of 25
10 · median 355
Started
2025
with 8 others
Observational
25 of 164
4 open now
Primary completion
2026-03
later than 13 of 43 live
Registered
154th of 164
by date

Among the 164 studies in Colitis, Ulcerative with a site in Netherlands, this one is the 24th largest by planned enrollment of the 25 observational ones that give a count, is one of 9 that started in 2025, is one of 25 observational ones, reaches primary completion later than 13 of the 43 other live ones, and was the 154th registered.

Colitis, Ulcerative

1,857 studies on the registry are indexed under Colitis, Ulcerative; 472 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

25 of the 164 studies in Colitis, Ulcerative with a site in Netherlands are open now. Recruiting first, the newest first:

19 more — sign in →

All 25 open studies →

A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →

Who these studies take

Of the 305 Colitis, Ulcerative studies recruiting now, 135 (44%) set no upper age limit and 134 (44%) stop at 75 or younger; 70 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 164 studies in Colitis, Ulcerative with a site in Netherlands, or all of them as a file.
02

Study summary

The goal of this observational pilot study with invasive measurements is to explore whether an ingestible sensor pill can be of use in diagnosis or monitoring of disease in patients with ulcerative colitis or colorectal cancer. The main questions it aims to answer are:

  • which changes in bowel environment can the sensor pill measure in ulcerative colitis and colorectal cancer before and after treatment?
  • how practical, effective and user-friendly is the sensor pill for measuring bowel environment in patients with bowel disease?

Participants will:

  • take one sensor pill before treatment and take one sensor pill three months after (start of) treatment;
  • monitor sensor pill bowel exit using a small wearable device;
  • answer a questionnaire on experience with the sensor pill;
  • receive an extra bowel ultrasound (non-endoscopic) three months after start of treatment (only for participants with ulcerative colitis).
Read the detailed description

Rationale: The gold standard diagnostic tool for inflammatory bowel disease (IBD) and colorectal carcinoma (CRC) is endoscopy, which can be burdensome for patients. The future of IBD care demands novel, minimally invasive biomarkers for personalized care and CRC screening programs could greatly benefit from new minimally invasive diagnostic tools. Oxidative stress plays a significant role in the progression of gut inflammation and colorectal cancer. Using an ingestible sensor, we aim to measure oxidation-reduction potential (ORP) directly in the gut. We hypothesize that it is feasible to measure intestinal ORP with an ingestible sensor and expect that ORP levels are elevated in patients with active ulcerative colitis (UC) and CRC before treatment, compared to after treatment.

Objective: Measurement of intestinal oxidation-reduction potential using a smart sensing ingestible and its relation to active UC and CRC.

Study design: Observational, exploratory study with invasive measurements.

Study population: 5 patients ≥ 18 years of age with UC and 5 patients ≥ 18 years of age with CRC

Main study parameters/endpoints: The main study parameter is colonic ORP profiles measured with the ingestible sensor ingestible compared before and after treatment for UC and CRC.

Nature and extent of the burden and risks associated with participation, benefit and group relatedness: Risk associated with participation are deemed low. Medical or surgical treatment is not altered in any way. Patients with UC will receive an additional IUS. The GISMO GEN1 ingestible device (size 21.8 mm x 7.64 mm) is an investigational tool deemed safe for human use in clinical settings, with risks detailed in the IMDD. Device exit will be tracked via the temperature sensor of the ingestible sensor. If exit is not confirmed after 14 days, an X-ray will confirm whether the device is still in the gastrointestinal tract. If visible on the X-ray, a medical specialist will determine further action, which may include laxatives or surgery, with costs covered by the research team. If X-ray examination is necessary, the participant may experience a maximum radiation exposure of 0.10 mSv. Participant burden is low; time investment including study visits, device checks and questionnaire is estimated around 4 hours in total. Main burden is expected to be the continuous wearing of the base device as long as the ingestible sensor remains in the body.

03

Conditions studied

  • Ulcerative Colitis (UC)
  • Colorectal Cancer (CRC)

Keywords

  • Ulcerative Colitis
  • Colorectal cancer
  • Sensor
  • Redox
  • Oxidation reduction potential
  • Ingestible
  • Sensor pill
  • Inflammatory bowel disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

This study will be performed in outpatients ≥18 years old. Five patients will be included with moderately to severely active UC, starting new treatment; five patients with colorectal adenocarcinoma, planned for surgery.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

(For all participants:)

  • Age ≥ 18 years old;
  • willing and able to provide ;
  • defaecation pattern: generally at least one defaecation per 48 hours.

(For the UC group:)

  • Diagnosis of UC confirmed by clinical, endoscopic, and/or histological evidence prior to screening as per standard criteria;
  • moderately to severely active UC determined by intestinal ultrasound (bowel wall thickness (BWT) > 3 mm), starting treatment or requiring change in treatment due to non-response to their existing treatment;
  • starting or optimizing treatment for colitis (including aminosalicylates, oral , thiopurines, biologics and small molecules).

(For the CRC group:)

  • Diagnosis of non-obstructing non-locally advanced colorectal adenocarcinoma;
  • ready/planned for surgery of CRC.

Exclusion criteria

Exclusion Criteria:

(For all participants:)

  • (BMI) > 30 kg/m\^2;
  • known obstruction, stricture or stenosis in the gastrointestinal tract not attributable to current inflammation or tumour, potentially blocking ingestible passage. Determined as per discretion of gastroenterologist/oncologist using standard procedural clinical diagnostic or imaging techniques;
  • history of complex bowel resection or recent intra-abdominal surgery (\< 3 months);
  • known abdominal adhesions;
  • swallowing disorders, including achalasia or oropharyngeal dysfunction;
  • ongoing infections;
  • known to be pregnant, lactating or actively trying to get pregnant (self-reported);
  • short bowel syndrome or ostomy;
  • only parenteral diet;
  • pacemaker or other implantable electronic devices;
  • planned magnetic resonance imaging (MRI) procedure during the ingestible meaurement period;
  • unwilling to undergo an X-ray examination (in the case ingestible exit cannot be confirmed);
  • participation in other medical interventional/Wet medisch-wetenschappelijk onderzoek (WMO)-compliant reearch;
  • participant is working (as medical personnel) in a professional healthcare facility (intensive care, emergency room, surgery rooms, clinics, patient rooms), military area (e.g. submarine, near radar installation), or heavy industrial area (e.g. power plants, automotive, mining, refineries) during the duration of the clinical investigation.

(For the CRC group:)

  • Diagnosis or strong suspicion of IBD;
  • planned treatment with chemotherapy or radiotherapy.

(For the UC population:)

  • Diagnosis or strong suspicion of colorectal adenocarcinoma;
  • use of rectal foam/enema during the measurement period.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
10 participants (estimated)
Patient registry
No

Groups and cohorts

  • Ulcerative colitis

    Device: Ingestion of sensor capsule (twice) · Behavioral: Device evaluation questionnaire · Device: Wearing device · Behavioral: Monitoring sensor capsule exit · Device: Placement of devices at home · Diagnostic Test: Follow-up intestinal ultrasound

  • Colorectal cancer

    Device: Ingestion of sensor capsule (twice) · Behavioral: Device evaluation questionnaire · Device: Wearing device · Behavioral: Monitoring sensor capsule exit · Device: Placement of devices at home

Interventions

  • DeviceIngestion of sensor capsule (twice)

    Ingestion of the GISMO GEN1 System, an ingestible sensor capsule which measures pH, temperature and oxidation reduction potential (ORP) in the intestines.

    Also known as: GISMO GEN1 System

  • BehavioralDevice evaluation questionnaire

    A 16-item online questionnaire to assess participant's experiences with the ingestible sensor capsule after the study measurements.

  • DeviceWearing device

    Participants will wear a small device on a soft belt around their waist during study measurements with the sensor capsules.

  • BehavioralMonitoring sensor capsule exit

    Participants are instructed to press a button on the wearable device when they use the toilet for defaecation and wait with flushing to toilet until the wearable device indicates (using colored LEDs) that the toilet can be flushed and 1) that the sensor capsule is still in the body and study measurements continue or 2) that the sensor capsule has likely been excreted via the feces and the participant has to contact the research team to confirm exit.

  • DevicePlacement of devices at home

    Participants do not have to wear the device around the waist during sleeping. For optimal monitoring of sensor capsule exit during the nights, a second device will be placed on the participant's bedside table/close to the bed and a third device will be placed close to the toilet that the participant usually uses during the night.

  • Diagnostic testFollow-up intestinal ultrasound

    At 3 months after treatment initiation, participants with ulcerative colitis will undergo a follow-up intestinal ultrasound (IUS) (non-endoscopic) outside of routine care to assess treatment response.

06

What researchers measure

Primary outcomes

  1. Intestinal ORP measurements

    ORP profile in the colon using the GISMO GEN1 System in patients with UC or CRC.

    Time frame: Baseline and at 3 months after start of treatment.

  2. Disease activity (SCCAI)

    UC disease activity as determined by the Simple Clinical Colitis Activity Index

    Time frame: Baseline and 3 months after start of treatment.

  3. Disease activity (FC)

    UC disease activity as determined by the faecal calprotectin (in microgram/gram)

    Time frame: Baseline and at 3 months after treatment start.

  4. Tumor stage

    TNM tumor stage as recorded in pathology report.

    Time frame: Directly after surgical resection

  5. Tumor size

    Tumor size as recorded in surgery report.

    Time frame: Directly after surgical resection

  6. Tumor resection margin status

    Residual tumor at the primary site after surgical resection as classified in pathology report.

    Time frame: Directly after surgical resection

  7. Tumor differentiation grade

    Tumor differentiation grade as recorded in pathology report.

    Time frame: Directly after surgical resection

Secondary outcomes

  1. Intestinal pH

    Intestinal pH measured with the ingestible sensor capsule.

    Time frame: From enrollment to 3 months after start of treatment.

  2. Area of inflammation

    Area of inflammation in patients with UC, as recorded in the intestinal ultrasound report.

    Time frame: Directly after intestinal ultrasound.

  3. Tumour location

    Tumor location in patients with CRC as recorded in the surgery report.

    Time frame: Directly post-surgery.

  4. Ingestible transit time.

    Time from ingestion to defaecation in hours.

    Time frame: Baseline and at 3 months after start of treatment.

  5. Data coverage

    Data coverage of recordings with the ingestible sensor capsule in minutes of data recorded as percentage of transit time in minutes (%)

    Time frame: Baseline and at 3 months after start of treatment

  6. Participant experience

    Participant experience determined with a satisfaction questionnaire.

    Time frame: Up to 1 month after exit of the post-treatment ingestible sensor capsule measurement period.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — The data that supports the findings of this study can be made available upon request to the corresponding author within the regulations of the applicable regulations and ethical considerations.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Mar 2026, 8 months after the start.

Of 188 non-industry observational studies under Colitis, Ulcerative, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 119. This study's planned 8 months is below that.

Counting every sponsor, half of 271 studies reached it within 47 months; a quarter within 29 and three quarters within 90.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 26, 2025
First posted
Jul 1, 2025
StartActual
Jul 1, 2025
Primary completionEst.
Mar 1, 2026
CompletionEst.
May 1, 2026
Last update
Aug 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07046468
Collaborators
Stichting IMEC-NL
Responsible party
Sponsor
First posted
Jul 1, 2025
Start date
Jul 1, 2025
Primary completion
Mar 1, 2026 (estimated)
Completion
May 1, 2026 (estimated)
Last update
Aug 29, 2025

Study contacts

Lotte R Hazeleger, Master of Science
Contact
lotte.hazeleger@radboudumc.nl
+31650008309
Marjolijn Duijvestein, MD PhD
Contact
marjolijn.duijvestein@radboudumc.nl
Marjolijn Duijvestein, MD PhD
principal investigator · Radboud University Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion